Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion ...

Regeneron’s Q1 2025 performance was anchored by continued growth of key products, particularly Dupixent, while facing some headwinds in its ophthalmology franchise. As shown in the following ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported first-quarter profit of $808.7 million. The Tarrytown, New York-based company said it ...

Q1 earnings and revenue miss expectations ... Grab the top 3 stocks to buy right here. Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% ...

Introduction & Market Context Regeneron Pharmaceuticals Inc (NASDAQ: REGN) released its Q1 2025 corporate presentation on April 29, 2025, highlighting continued growth of its flagship products amid ...